- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07780188
Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) (Beef+)
19 agosto 2026 aggiornato da: Heidi Vanden Brink, Texas A&M University
Effect of Increasing Lean Beef Intake as Part of a Healthy Meal Plan on Glycemic Control in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)
This pilot randomized controlled study will plan to enroll 36 adolescent females with Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) to evaluate the effectiveness and feasibility of a tailored dietary intervention which will be termed "Beef+", that will emphasize the incorporation of unprocessed, lean beef (<10% fat) as part of a healthy meal plan to improve glycemic control, diet quality, and health-related quality of life
Panoramica dello studio
Stato
Reclutamento
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Youth-onset Type 2 Diabetes (T2D) is a chronic disease characterized by accelerated beta cell decline and severe insulin resistance (IR).
Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a well-established independent risk factor for youth-onset T2D.
A first line of treatment for PCOS is lifestyle intervention; however, there is a paucity of evidence evaluating the effectiveness of nutritional strategies in adolescents with PCOS.
The overarching goal of the pilot study, termed Beef+, is to replace intake of high fat, processed red meat products with lean beef ("Beef") prepared as part of healthy meals that target increased vegetable and complex carbohydrate intake per the Dietary Guidelines for Americans ("+") and reducing intake of saturated fat, sodium, and added sugar.
We will test the hypothesis that incorporating lean beef as part of a healthy meal plan will improve glucoregulation (Aim 1), enhance overall diet quality and satiety (Aim 2), and be a feasible and acceptable dietary intervention strategy that improves participant and household health-related quality of life (Aim 3).
Tipo di studio
Interventistico
Iscrizione (Stimato)
36
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Contatto studio
- Nome: Heidi K Vanden Brink, PhD, MSc, RDMS
- Numero di telefono: 979-321-7073
- Email: heidi.vandenbrink@ag.tamu.edu
Luoghi di studio
-
-
Texas
-
College Station, Texas, Stati Uniti, 77843
- Reclutamento
- Texas A&M AgriLife
-
Contatto:
- Heidi Vanden Brink
- Numero di telefono: 979--321-7073
- Email: heidi.vandenbrink@ag.tamu.edu
-
Sub-investigatore:
- Michele Garant, DO
-
Sub-investigatore:
- Seung-Yeon "Shawn" Ha, PhD
-
Sub-investigatore:
- Lilian Ademu, PhD
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Bambino
Accetta volontari sani
No
Descrizione
Inclusion Criteria:
- Female Adolescent
- 11-17 years old
- Suspected or confirmed diagnosis of PCOS
- ≥1-year post-menarche
- BMI ≥85th percentile for age/height
- Able to read and speak English
Exclusion Criteria:
- Medications affecting glucoregulation, metabolic health, and/or appetite (e.g., metformin, GLP-1)
- Unable or unwilling to eat beef
- Pregnant or planning pregnancy during study
- HbA1c ≥6.5%
- Unwilling or unable to complete study procedures
- Conditions affecting ability to complete study procedures or the intervention such as gastrointestinal diseases or syndromes, bleeding disorders, ongoing or unresolved eating disorder)
- Conditions affecting reproductive function other than PCOS
- Conditions that may interfere with continuous glucose monitor (CGM) application or use, including dermatological conditions such as eczema or allergies/reactions to medical adhesives
Conditional Exclusion Criteria:
- Current use of hormonal contraceptives if in the suspected PCOS group (allowable if current for at least the previous 3 months with physician-confirmed PCOS)
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Nessun intervento: Control/Usual Lifestyle with optional Delayed Intervention
Participants randomized to usual lifestyle will continue with their usual lifestyle/ diet.
Participants will undergo all scheduled study procedures.
Upon completion of the 12-week of usual lifestyle, participants randomized to the delayed onset control group will be offered one month of the dietary intervention.
The delayed intervention is optional.
|
|
|
Sperimentale: Beef+
|
Adolescents will be instructed to consume a minimum of 1 (3oz) serving per day of cooked unprocessed, lean (<10% fat) beef (21 oz/week) for 12 weeks.
To facilitate adoption, the intervention will be offered at the household level, but it is not a requirement.
The intervention is a multi-modal behavior change intervention with three overarching components: modifying beef intake, consuming beef in healthy meals, and the research team purchasing the beef needed for the intervention.
To facilitate adoption of lean beef as part of a healthy diet, a study RDN will meet with the participant and at least one representative parent/guardian at bi-weekly check-ins to provide tailored dietary support and develop an implementation plan.
A financial supplement of $100/month will be provided offset grocery costs.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in HbA1c
Lasso di tempo: Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
HbA1c measured as point of care using A1CNow+ point-of-care analyzer, HbA1c will also serve as a safety endpoint.
|
Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in 2-hour Fasting Glucose
Lasso di tempo: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Derived from a 75g oral glucose tolerance test (OGTT) as a measure of glycemic variability
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Dropout rate
Lasso di tempo: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Drop-out and the reason for drop-out will be recorded, and in both the intervention and usual lifestyle groups will be reported.
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Change in Matsuda Index
Lasso di tempo: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Derived from a 75g oral glucose tolerance test (OGTT), measure of insulin sensitivity
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Change in Insulinogenic Index
Lasso di tempo: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Derived from the 75g oral glucose tolerance test (OGTT), measure of insulin sensitivity
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Change in Disposition Index
Lasso di tempo: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Derived from a 75g oral glucose tolerance test (OGTT), measure of insulin sensitivity
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Change in 2nd Phase Insulin Release
Lasso di tempo: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Derived from a 75g oral glucose tolerance test (OGTT), as a measure of insulin sensitivity
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Change in Time in Range
Lasso di tempo: Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
Derived from blinded Continuous Glucose Monitor (CGM) wear, a measure of glycemic variability
|
Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
|
Change in Continuous Overall Net Glycemic Action (CONGA)
Lasso di tempo: Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
Derived from blinded Continuous Glucose Monitor (CGM) wear, as a metric of glycemic variability
|
Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
|
Change in Glycemic Risk Assessment in Diabetes Education (GRADE)
Lasso di tempo: Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
Derived from blinded Continuous Glucose Monitor (CGM) wear, measure of glycemic variability
|
Baseline, Week 6 and Week 12 of Intervention or Usual Lifestyle
|
|
Change in Diet Quality - Dietary Recalls
Lasso di tempo: Baseline and Week 14
|
This will be assessed from 24-hour diet recalls and evaluated via Healthy Eating Index (HEI).
|
Baseline and Week 14
|
|
Change in Diet Quality - Skin Carotenoids
Lasso di tempo: Baseline and Week 14
|
Skin carotenoids will be measured through the Veggie Meter ®, which uses reflection spectroscopy to estimate skin carotenoid levels.
Three scans will be taken on your non-dominant ring finger.
After each scan, a dial gauge and a score will appear on the screen.
A final score, calculated as the average of the three scans, will range from 0 to 800.
Higher scores indicate greater fruit and vegetable intake.
|
Baseline and Week 14
|
|
Change in Perceived Hunger
Lasso di tempo: Baseline and Week 14
|
This will be measured through an Appetite/Satiety Questionnaire adapted from commonly used appetite assessment methods and previously applied in dietary intervention research.
Participants will report their general appetite and satiety experiences using six items assessing hunger frequency, strength of hunger before meals, fullness after eating, desire to eat when food is available, thoughts about food, and satisfaction after eating.
Responses are recorded using a 100-mm visual analogue scale implemented as a 0-100 slider (0 = lowest intensity or frequency; 100 = highest intensity or frequency).
Participants will be instructed to move the slider to reflect how strongly each statement describes their typical experience.
Data collected will be used to evaluate changes in perceived hunger and fullness throughout the intervention.
|
Baseline and Week 14
|
|
Change in incident Pre and Type 2 Diabetes
Lasso di tempo: Baseline, Week 6, and Week 12 of Intervention or Usual Lifestyle
|
Type 2 Diabetes is defined as HbA1c >6.5%.
|
Baseline, Week 6, and Week 12 of Intervention or Usual Lifestyle
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Compliance- Lean beef intake by self-report
Lasso di tempo: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Intake of lean beef, assessed via 24-hour diet recalls
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Compliance - Daily Survey
Lasso di tempo: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Intake of lean beef, assessed through daily logs of beef intake by providing portion sized objects that align with serving sizes and ask participants to take photos of their meals with the portion estimator, to ensure that both the meal planning is followed and portion sizes are met.
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Compliance - Blood Biomarkers
Lasso di tempo: Baseline and Week 12 of Intervention or Usual Lifestyle
|
Serum hemoglobin will also be assessed as a metric of compliance.
|
Baseline and Week 12 of Intervention or Usual Lifestyle
|
|
Participants' Quality of Life
Lasso di tempo: Baseline and and Week 14
|
This will be measured through the Pediatric Quality of Life (PedsQL) questionnaire.
It includes 23 questions and is scored by reverse-scoring items and linearly transforming them to a 0-100 scale.
Higher scores mean better health-related quality of life.
|
Baseline and and Week 14
|
|
Household Quality of Life
Lasso di tempo: Baseline and Week 14
|
This will be measured through the Adapted version of the Family Impact Module of the Pediatric Quality of Life (PedsQL).
This questionnaire includes 36 questions and includes a 5-point Likert scale (0 to 4), reverse-scored and linearly transformed to a 0-100 scale.
Higher scores show better parent health-related quality of life and family functioning with less negative impact.
|
Baseline and Week 14
|
|
Exploratory Analysis - Lean Beef
Lasso di tempo: Baseline and Week 14
|
An exploratory analysis will reveal whether lean beef was directly associated with any change in glycemic outcome over time
|
Baseline and Week 14
|
|
Economic Evaluation of the Intervention (Ancillary Study, Optional)
Lasso di tempo: Baseline and Week 14
|
An exploratory economic evaluation will estimate household food-related costs associated with participation in the intervention as an ancillary study.
Parents or legal guardians will be invited to record and provide receipts for costs related to groceries or food purchased for at-home meal preparation, as well as for meals purchased outside the home, including at restaurants and fast-food venues
|
Baseline and Week 14
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Investigatori
- Investigatore principale: Heidi K Vanden Brink, PhD, MSc, RDMS, Texas A&M University
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Stimato)
1 settembre 2026
Completamento primario (Stimato)
30 aprile 2028
Completamento dello studio (Stimato)
30 aprile 2028
Date di iscrizione allo studio
Primo inviato
7 agosto 2026
Primo inviato che soddisfa i criteri di controllo qualità
19 agosto 2026
Primo Inserito (Effettivo)
21 agosto 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
21 agosto 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
19 agosto 2026
Ultimo verificato
1 agosto 2026
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Malattie del sistema endocrino
- Processi patologici
- Disturbi della nutrizione
- Neoplasie
- Malattie urogenitali maschili
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Ipernutrizione
- Peso corporeo
- Malattie genitali, femmina
- Malattie ovariche
- Malattie annessiali
- Disturbi gonadici
- Malattie della pelle
- Anomalie congenite
- Malattie dei capelli
- Cisti ovariche
- Cisti
- Disturbi dello sviluppo sessuale
- Anomalie urogenitali
- Virilismo
- 46, XX Disturbi dello sviluppo sessuale
- Sindrome adrenogenitale
- Malattie e anomalie congenite, ereditarie e neonatali
- Condizioni patologiche, segni e sintomi
- Malattie nutrizionali e metaboliche
- Malattie della pelle e del tessuto connettivo
- Segni e sintomi
- Sovrappeso
- Sindrome delle ovaie policistiche
- Irsutismo
- Disturbi delle mestruazioni
- Iperandrogenismo
- Cibo
- Dieta, cibo e nutrizione
- Fenomeni fisiologici
- Cibo e bevande
- Carne
- Carne Rossa
Altri numeri di identificazione dello studio
- IRB#STUDY2026-0483
- #2681 (Altro identificatore: National Cattlemen's Beef Association, a contractor to the Beef Checkoff)
- Lab Research Funds (Altro identificatore: Texas A&M AgriLife)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Descrizione del piano IPD
Individual participant data is not anticipated to be shared on a publicly available database because this is not a federally funded study and given the nature of the data collected and vulnerable population.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .